中国医院用药评价与分析Issue(6)：497-500,4.
吉非替尼与GP方案治疗晚期非小细胞肺癌的疗效比较
Efficacy Comparison of Gefitinib versus GP Regimen for Advanced Non-small Cell Lung Cancer
梁云 1邹秀珍1
作者信息
- 1. 清远市阳山县人民医院，广东清远 513100
- 折叠
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and safety of gefitinib versus GP regimen(gemcitabine plus cisplatin)for ad-vanced non-small cell lung cancer (NSCLC). METHODS:The clinical data of 96 patients with advanced NSCLC were analyzed retrospectively. 48 cases in observation group were administered with gefitinib,and another 48 in control group were given GP regi-men. The therapeutic efficacy and adverse reactions were recorded. RESULTS:The disease control rate in the observation group was significantly better than in the control group (P<0.05),and the symptoms like chest pain,bloody sputum,compression superior vena cava syndrome(SVCS)relieved rapidly(P<0.05);the quality of life improved significantly(P<0.05)and the adverse reac-tions were mild in these patients. CONCLUSIONS:Gefitinib treatment resulted in remarkable efficacy for those patients who can’t tolerate or reject using chemotherapy and it can improve the quality of life yet with mild adverse drug reactions which thus enjoys bright future in clinical application.关键词
吉非替尼/吉西他滨/顺铂/非小细胞肺癌Key words
Gefitinib/Gemcitabine/Cisplatin/Non-small cell lung cancer分类
医药卫生引用本文复制引用
梁云,邹秀珍..吉非替尼与GP方案治疗晚期非小细胞肺癌的疗效比较[J].中国医院用药评价与分析,2014,(6):497-500,4.
